

Adherium exhibiting at 2022 British Thoracic Society (BTS) Winter Meeting

Melbourne, Australia – 24 November 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce it will be exhibiting at 2022 British Thoracic Society (BTS) Winter Meeting in London on 23-25 November in booth #12 with Helicon Health (“Helicon”), its conference co-sponsor.

Attended by leading clinical academics, this prestigious conference showcases cutting-edge scientific research in respiratory medicine, including presentations of original data. This is the first face-to-face meeting since 2019 and will be held at the QEII Centre, providing ample opportunity for those one-to-one interactions with clinicians, allied health professionals and scientific colleagues from within the UK and abroad.

Adherium’s full range of Hailie® digital sensors along with Helicon’s comprehensive remote patient monitoring platform will be on display for the over 2,000 healthcare professionals expected to attend.

The Hailie sensor attaches to a patient’s asthma or COPD medication inhaler and connects via the Hailie app to Helicon’s innovative platform. The combination creates the most advanced quality care for respiratory patients that are on virtual wards, at home and in any other remote setting for the clinical team to make timely decisions on patient care.

Adherium’s partnership with Helicon - a medical technology development company, NHS-focused contract research partner and specialised medical device accelerator - was announced in June 2022 and it marks a significant milestone in the Company’s commercial strategy expanding market access in the UK as well as accelerating adoption.

For more details, please visit: <https://www.brit-thoracic.org.uk/education-and-events/winter-meeting/>

-ENDS-



About Adherium (ASX: ADR)

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at www.adherium.com

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries: WE Communications
WE-AUAdherium@we-worldwide.com